Histology of cervical intraepithelial neoplasia and the role of biomarkers

Best Practice and Research: Clinical Obstetrics and Gynaecology

Volumn 25, Issue 5, 2011, Pages 605-615

  Martin, Cara M ^a,b   O'Leary, John J ^a,b,c  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b Pathology Research Laboratory   (Ireland)

^c ST JAMES S HOSPITAL   (Ireland)

Author keywords

Cervical intraepithelial neoplasia; Cyclin dependent kinase inhibitor p16; E6 E7 oncogenes; Human papillomavirus; Ki 67 antigen

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; KI 67 ANTIGEN; PROTEIN E6; PROTEIN E7; TUMOR MARKER; CELL CYCLE PROTEIN; DNA BINDING PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE II ALPHA; MYBL2 PROTEIN, HUMAN; NUCLEAR PROTEIN; TRANSACTIVATOR PROTEIN; TUMOR ANTIGEN;

CANCER CLASSIFICATION; CARCINOGENESIS; CLINICAL ASSESSMENT; DIFFERENTIAL DIAGNOSIS; HISTOPATHOLOGY; HUMAN; OBSERVER VARIATION; PRECANCER; PRIORITY JOURNAL; PROGNOSIS; REPRODUCIBILITY; REVIEW; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS; ALPHAPAPILLOMAVIRUS; CANCER GRADING; DNA PROBE; FEMALE; GENETICS; METABOLISM; PATHOLOGY; UTERINE CERVIX TUMOR; VIROLOGY;

ALPHAPAPILLOMAVIRUS; ANTIGENS, NEOPLASM; CELL CYCLE PROTEINS; CERVICAL INTRAEPITHELIAL NEOPLASIA; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA PROBES, HPV; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; FEMALE; HUMANS; KI-67 ANTIGEN; NEOPLASM GRADING; NUCLEAR PROTEINS; PROGNOSIS; TRANS-ACTIVATORS; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 84858261304     PISSN: 15216934     EISSN: 15321932     Source Type: Journal    
DOI: 10.1016/j.bpobgyn.2011.04.005     Document Type: Review

References (78)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C & Parkin DM. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet].Lyon. Available from:. France: International Agency for Research on Cancer, 2010 http://globocan.iarc.fr.
2. An introduction to cervical intraepithelial neoplasia (CIN). In Sellors JW & Sankaranarayanan R (eds.). Colposcopy and treatment of cervical intraepithelial neoplasia: a beginners manual 2003, pp. 13-20.
3. Walboomers JM, Jacobs MV, Manos MM et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-19. (Pubitemid 29406813)
4. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002; 2: 342-350. (Pubitemid 37328947)
5. Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond) 2006; 110: 525-541. (Pubitemid 43736116)
6. Sellors JW, Mahoney JB, Kaczorowski J et al. Prevalence and predictors of human papillomavirus infection in women in Ontario, Canada. Can Med Assoc J 2000; 163: 503-508.
7. Andersson S, Safari H, Mints M et al. Type distribution, viral load and integration status of high-risk human papillomaviruses in pre-stages of cervical cancer (CIN). Br J Cancer 2005; 92: 2195-2200. (Pubitemid 40966257)
8. Derchain SF, Rabelo-Santos SH, Sarian LO et al. Human papillomavirus DNA detection and histological findings in women referred for atypical glandular cells or adenocarcinoma in situ in their Pap smears. Gynecol Oncol 2004; 95: 618-623. (Pubitemid 39592530)
9. Tjalma WA, Van Waes TR, Van den Eeden LE et al. Role of human papillomavirus in the carcinogenesis of squamous cell carcinoma and adenocarcinoma of the cervix. Best Pract Res Clin Obstet Gynaecol 2005; 19: 469-483. (Pubitemid 41263800)
10. Cuschieri KS, Whitley MJ & Cubie HA. Human papillomavirus type specific DNA and RNA persistence-implications for cervical disease progression and monitoring. J Med Virol 2004; 73: 65-70. (Pubitemid 38429149)
11. Molden T, Nygard JF, Kraus I et al. Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV-proofer and consensus PCR: a 2-year follow-up of women with ASCUS or LSIL Pap smear. Int J Cancer 2005; 114: 973-976.
12. Castellsagué X & Muñoz N. Cofactors in human papillomavirus carcinogenesis-role of parity, oral contraceptives, and tobacco smoking. J Natl Cancer Inst Monogr 2003; 31: 20-28.
13. Moscicki AB, Ma Y, Wibbelsman C et al. Rate of and risks for regression of cervical intraepithelial neoplasia 2 in adolescents and young women. Obstet Gynecol 2010; 116: 1373-1380.
14. Moscicki AB, Shiboski S, Hills NK et al. Regression of low-grade squamous intra-epithelial lesions in young women. Lancet 2004; 364: 167-883.
15. Cox JT, Schiffman M, Solomon D, & ASCUS-LSIL Triage Study (ALTS) Group. Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy. Am J Obstet Gynecol 2003; 188: 1406-1412. (Pubitemid 36741266)
16. Goldie SJ, Kohli M, Grima D et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004; 96: 604-615. (Pubitemid 38584984)
17. Castle PE, Schiffman M, Wheeler CM & Solomon D. Evidence for frequent regression of cervical intraepithelial neoplasiagrade 2. Obstet Gynecol 2009; 113: 18-25.
18. Schiffman M & Rodríguez AC. Heterogeneity in CIN3 diagnosis. Lancet Oncol 2008; 9: 404-406. (Pubitemid 351618081)
19. Rodríguez AC, Schiffman M, Herrero R et al. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst 2010; 102: 315-324.
20. Wright Jr. TC, Massad LS & Dunton CJ. 2006 American Society for Colposcopy and Cervical Pathology-sponsored Consensus Conference. 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. J Low Genit Tract Dis 2007; 11: 223-239. (Pubitemid 47530910)
21. Erratum in: J Low Genit Tract Dis 2008; 12: 63.
22. Pyeon D, Pearce SM, Lank SM et al. Establishment of human papillomavirus infection requires cell cycle progression. PLoS Pathog 2009 Feb; 5: e1000318.
23. Longworth MS & Laimins LA. Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol Mol Biol Rev 2004; 68: 362-372. (Pubitemid 38756870)
24. Woodman CB, Collins SI & Young LS. The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer 2007; 7: 11-22. (Pubitemid 46020844)
25. Dalla Palma P, Giorgi Rossi P, Collina G, & NTCC Pathology Group. The reproducibility of CIN diagnoses among different pathologists: data from histology reviews from a multicenter randomized study. Am J Clin Pathol 2009; 132: 125-132.
26. Parker MF, Zahn CM, Vogel KM et al. Discrepancy in the interpretation of cervical histology by gynecologic pathologists. Obstet Gynecol 2002; 100: 277-280. (Pubitemid 34874790)
27. McCluggage WG, Bharucha H, Caughley LM et al. Interobserver variation in the reporting of cervical colposcopic biopsy specimens: comparison of grading systems. J Clin Pathol 1996; 49: 833-835. (Pubitemid 26338564)
28. Robertson AJ, Anderson JM, Beck JS et al. Observer variability in histopathological reporting of cervical biopsy specimens. J Clin Pathol 1989; 42: 231-238. (Pubitemid 19077263)
29. Stoler MH, Schiffman M, & Atypical Squamous Cells of Undetermined Significance-Low-Grade Squamous Intraepithelial Lesion Triage Study (ALTS) Group. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA 2001; 285: 1500-1505. (Pubitemid 32221899)
30. Martin CM, Kehoe L, Spillane CO et al. Gene discovery in cervical cancer: towards diagnostic and therapeutic biomarkers. Mol Diagn Ther 2007; 11: 277-290. (Pubitemid 350014792)
31. Erratum in Mol Diagn Ther 2007; 11: 411.
32. Cotton S, Sharp L, Little J, et alTrial Of Management of Borderline and Other Low-grade Abnormal Smears Group. The role of human papillomavirus testing in the management of women with low-grade abnormalities: multicentre randomised controlled trial. BJOG 2010; 117: 645-659.
33. ALTS Group. A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations. Am J Obstet Gynecol 2003; 188: 1393-1400.
34. ALTS Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 2003; 188: 1383-1392.
35. Szarewski A, Ambroisine L, Cadman L et al. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol Biomarkers Prev 2008; 17: 3033-3042.
36. Burger EA, Kornør H, Klemp M et al. HPV mRNA tests for the detection of cervical intraepithelial neoplasia: a systematic review. Gynecol Oncol 2010 (Epub ahead of print).
37. Kruse AJ, Baak JP, Janssen EA et al. Low- and high-risk CIN 1 and 2 lesions: prospective predictive value of grade, HPV, and Ki-67 immuno-quantitative variables. J Pathol 2003; 199: 462-470. (Pubitemid 36411223)
38. Kruse AJ, Baak JP, de Bruin PC et al. The HS. Ki-67 immunoquantitation in cervical intraepithelial neoplasia (CIN): a sensitive marker for grading. J Pathol 2001; 193: 48-54. (Pubitemid 32051112)
39. Pirog EC, Baergen RN, Soslow RA et al. Diagnostic accuracy of cervical low-grade squamous intraepithelial lesions is improved with MIB-1 immunostaining. Am J Surg Pathol 2002; 26: 70-75. (Pubitemid 34019994)
40. Kruse AJ, Baak JP, Janssen EA et al. Ki67 predicts progression in early CIN: validation of a multivariate progression-risk model. Cell Oncol 2004; 26: 13-20. (Pubitemid 39108239)
41. Walts AE & Bose S. p16, Ki-67, and BD ProExC immunostaining: a practical approach for diagnosis of cervical intraepithelial neoplasia. Hum Pathol 2009; 40: 957-964.
42. Murphy N, Ring M, Killalea AG et al. p16INK4A as a marker for cervical dyskaryosis: CIN and cGIN in cervical biopsies and ThinPrep smears. J Clin Pathol 2003; 56: 56-63. (Pubitemid 36132476)
43. Murphy N, Ring M, Heffron CC et al. p16INK4A, CDC6, and MCM5: predictive biomarkers in cervical preinvasive neoplasia and cervical cancer. J Clin Pathol 2005; 58: 525-534. (Pubitemid 40646875)
44. Klaes R, Friedrich T, Spitkovsky D et al. Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 2001; 92: 276-284. (Pubitemid 32225381)
45. Sano T, Oyama T, Kashiwabara K et al. Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol 1998; 153: 1741-1748. (Pubitemid 28550662)
46. Wang SS, Trunk M, Schiffman M et al. Validation of p16INK4a as a marker of oncogenic human papillomavirus infection in cervical biopsies from a population based cohort in Costa Rica. Cancer Epidemiol Biomarkers Prev 2004; 13: 1355-1360. (Pubitemid 39071561)
47. Carozzi F, Confortini M, Dalla Palma P, et al New Technologies for Cervival Cancer Screening (NTCC)Working Group. Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. Lancet Oncol 2008; 9: 937-945.
48. Negri G, Vittadello F, Romano F et al. p16INK4a expression and progression risk of low-grade intraepithelial neoplasia of the cervix uteri. Virchows Arch 2004; 445: 616-620. (Pubitemid 40104537)
49. Tsoumpou I, Arbyn M, Kyrgiou M et al. p16(INK4a) immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and metaanalysis. Cancer Treat Rev 2009; 35: 210-220.
50. Bose S, Evans H, Lantzy L et al. p16(INK4A) is a surrogate biomarker for a subset of human papilloma virus-associated dysplasias of the uterine cervix as determined on the Pap smear. Diagn Cytopathol 2005; 32: 21-24. (Pubitemid 40024069)
51. Dray M, Russell P, Dalrymple C et al. p16(INK4a) as a complementary marker of high-grade intraepithelial lesions of the uterine cervix. I: experience with squamous lesions in 189 consecutive cervical biopsies. Pathology 2005; 37: 112-124. (Pubitemid 40593402)
52. Dijkstra MG, Heideman DA, de Roy SC, Rozendaal L et al. p16(INK4a) immunostaining as an alternative to histology review for reliable grading of cervical intraepithelial lesions. J Clin Pathol 2010; 63: 972-977.
53. Hariri J & Oster A. The negative predictive value of p16INK4a to assess the outcome of cervical intraepithelial neoplasia 1 in the uterine cervix. Int J Gynecol Pathol 2007; 26: 223-238.
54. Omori M, Hashi A, Nakazawa K, Yuminamochi T et al. Estimation of prognoses for cervical intraepithelial neoplasia 2 by p16INK4a immunoexpression and high-risk HPV in situ hybridization signal types. Am J Clin Pathol 2007; 128: 208-217. (Pubitemid 47262618)
55. Bergeron C, Ordi J, Schmidt D et al. Conjunctive p16INK4a testing significantly increases accuracy in diagnosing high-grade cervical intraepithelial neoplasia. Am J Clin Pathol 2010; 133: 395-406.
56. Klaes R, Benner A, Friedrich T et al. p16INK4a immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia. Am J Surg Pathol 2002; 26: 1389-1399. (Pubitemid 35239415)
57. Agoff SN, Lin P, Morihara J et al. p16(INK4a) expression correlates with degree of cervical neoplasia: a comparison with Ki-67 expression and detection of high-risk HPV types. Mod Pathol 2003; 16: 665-673. (Pubitemid 36871499)
58. Santin AD, Zhan F, Bignotti E et al. Gene expression profiles of primary HPV16- and HPV18-infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapy. Virology 2005; 20(331): 269-291. (Pubitemid 40075455)
59. Chen Y, Miller C, Mosher R et al. Identification of cervical cancer markers by cDNA and tissue microarrays. Cancer Res 2003; 15: 1927-1935. (Pubitemid 36460860)
60. Davidson B, Goldberg I, Lerner-Geva L et al. Expression of topoisomerase II and Ki-67 in cervical carcinoma-clinicopathological study using immunohistochemistry. APMIS 2000; 108: 209-215. (Pubitemid 30159001)
61. Shi J, Liu H, Wilkerson M et al. Evaluation of p16, MCM2, DNA Topoisomerase IIA and ProExC in cervical squamous intraepithelial lesions. Lab Investig 2007; 87(suppl 1): 214A.
62. Bell SP & Dutta A. DNA replication in eukaryotic cells. Annu Rev Biochem 2002; 71: 333-374. (Pubitemid 34800224)
63. Lei M & Tye BK. Initiating DNA synthesis: from recruiting to activating the MCM complex. J Cell Sci 2001; 114: 1447-1454. (Pubitemid 32427832)
64. Saxena S & Dutta A. Geminin-Cdt1 balance is critical for genetic stability. Mutat Res 2005; 569: 111-121. (Pubitemid 39643261)
65. Ishimi Y, Okayasu I & Kato C. Enhanced expression of Mcm proteins in cancer cells derived from uterine cervix. Eur J Biochem 2003; 270: 1089-1101. (Pubitemid 36384443)
66. Ha SA, Shin SM, Namkoong H et al. Cancer-associated expression of minichromosome maintenance 3 gene in several human cancers and its involvement in tumorigenesis. Clin Cancer Res 2004; 10: 8386-8395. (Pubitemid 40053401)
67. Murphy N, Ring M, Heffron CC et al. Quantitation of CDC6 and MCM5 mRNA in cervical intraepithelial neoplasia and invasive squamous cell carcinoma of the cervix. Mod Pathol 2005; 18: 844-849. (Pubitemid 40780519)
68. Badr RE, Walts AE, Chung F et al. A sensitive and specific marker of HPV-associated squamous lesions of the cervix. Am J Surg Pathol 2008; 32: 899-906.
69. Guo M, Baruch AC & Silva EG. Efficacy of p16 and ProExC immunostaining in the detection of high-grade cervical intraepithelial neoplasia and cervical carcinoma. Am J Clin Pathol 2011; 135: 212-220.
70. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003; 3: 46-54. (Pubitemid 37328886)
71. Kim HS, Shiraki K & Park SH. Expression of survivin in CIN and invasive squamous cell carcinoma of uterine cervix. Anticancer Res 2002; 22: 805-808. (Pubitemid 34475232)
72. Branca M, Giorgi C, Santini D, et al HPV-Pathogen ISS Study Group. Survivin as a marker of cervical intraepithelial neoplasia and high-risk human papillomavirus and a predictor of virus clearance and prognosis in cervical cancer. Am J Clin Pathol 2005; 124: 113-121. (Pubitemid 40944383)
73. Borbely AA, Murvai M, Konya J et al. Effects of human papillomavirus type 16 oncoproteins on survivin gene expression. J Gen Virol 2006; 87: 287-294. (Pubitemid 43169253)
74. Ansieau S, Kowenz-Leutz E, Dechend R et al. B-MYB, a repressed trans-activating protein. J Mol Med 1997; 75: 815-819. (Pubitemid 27511556)
75. Bessa M, Joaquin M, Tavner F et al. Regulation of the cell cycle by B-Myb. Blood Cell Mol Dis 2001; 27: 416-421. (Pubitemid 32547838)
76. Sala A. B-MYB, a transcription factor implicated in regulating cell cycle, apoptosis and cancer. Eur J Cancer 2005; 41: 2479-2484. (Pubitemid 41540624)
77. Lam E, Morris JDH, Davies R et al. HPV16 E7 oncoprotein deregulates B-myb expression:correlation with targeting of p107/ E2F complexes. EMBO J 1994; 13: 871-878. (Pubitemid 24057518)
78. Astbury K, McEvoy L, Brian H, Spillane C, Sheils O, Martin C & O'Leary JJ. MYBL2 (B-MYB) in cervical cancer: putative biomarker. Int J Gynecol Cancer 2011 Feb; 21(2): 206-212. PMID:21270603.